Mustang Bio

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Alzamend Neuro

Cellectar BioSciences

ReShape Lifesciences

X4 Pharmaceuticals Inc

5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week

Webinar to be held on Thursday, December 16, 2021, at 2:30 p.m. ET

Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

WORCESTER, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2021.

Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

Agreement expands Mustang's pipeline of lentiviral gene therapies for SCID

Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency

Key opinion leader webinar on Thursday, December 16, 2021, at 2:30 p.m. ET Key opinion leader webinar on Thursday, December 16, 2021, at 2:30 p.m. ET

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting

Mustang Bio Inc (NASDAQ: MBIO) has been awarded a grant of approximately $2 million from the National Cancer Institute of the National Institutes of Health (NIH).  The two-year award will partially fund the Phase 1 trial to assess the safety, tolerability, and efficacy of MB-106 for relapsed or refractory B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia.

Mustang Bio Secures $2M NIH Grant For CAR T Cell Therapy Development

WORCESTER, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the company has been awarded a grant of approximately $2 million from the National Cancer Institute of the National Institutes of Health (“NIH”). This two-year award will partially fund the Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) or chronic lymphocytic leukemia (“CLL”).

Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas

WORCESTER, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, and members of the Mustang Leadership Team will participate in a fireside chat at Chardan's Virtual 5th Annual Genetic Medicines Conference, taking place on Tuesday, October 5, 2021, at 8:00 a.m. ET. The company will also participate in one-on-one meetings during the conference. A live webcast of the company's chat will be available on the Events page of the Investor Relations section of Mustang's website, www.mustangbio.com, for approximately 30 days after the meeting.

Mustang Bio to Participate in Chardan's Virtual 5th Annual Genetic Medicines Conference

Christine Brown, Ph.D., of City of Hope will present at the First Annual Conference on CNS Clinical Trials Co-sponsored by SNO and ASCO and the AACR Virtual Special Conference: Brain Cancer Christine Brown, Ph.D., of City of Hope will present at the First Annual Conference on CNS Clinical Trials Co-sponsored by SNO and ASCO and the AACR Virtual Special Conference: Brain Cancer

Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences

Mustang Bio (MBIO) has been struggling lately, but the selling pressure may be coming to an end soon.

Mustang Bio (MBIO) Sees Hammer Chart Pattern: Time to Buy?

Mustang Bio remains underfollowed despite having several therapies that have the potential to be major breakthroughs in some of the most notorious and hard-to-treat diseases. MBIO's share price is near the 52-week lows despite the company completing milestones and a few bullish catalysts ahead. Several programs are moving closer to their pivotal studies.

Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies

WORCESTER, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in September 2021.

Mustang Bio to Participate in Three September 2021 Investor Conferences

AEGON

Reddit penny stocks are heating up, here's 3 to watch right now The post Reddit Penny Stocks to Buy? 3 That You Probably Don't Know About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Reddit Penny Stocks to Buy? 3 That You Probably Don't Know About

WORCESTER, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2021.

Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights

The exclusively licensed platform has potential application for any tumor target

Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology

Sphere 3D

Altamira Therapeutics Ltd

Which penny stocks are investors watching this week? Here's 3 for your list The post Are These Penny Stocks Worth Watching This Week?

Are These Penny Stocks Worth Watching This Week? 3 For Your List

The European Medicines Agency has granted Priority Medicines designation to Mustang Bio Inc's (NASDAQ: MBIO) MB-107 for X-linked severe combined immunodeficiency (X-SCID) in newly diagnosed infants, also known as bubble boy disease. The Company is preparing to initiate a pivotal, multicenter Phase 2 clinical trial of MB-107 in newly diagnosed patients with X-SCID at the end of Q3.

Mustang Bio's Gene Therapy For Genetic Immunodeficiency Receives European PRIME Tag

WORCESTER, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the European Medicines Agency (“EMA”) has granted Priority Medicines (“PRIME”) designation to MB-107, its lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (“XSCID”) in newly diagnosed infants, also known as bubble boy disease.

Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

WORCESTER, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference, taking place virtually from June 21 - 23, 2021. The company will present on Wednesday, June 23, 2021, at 8:00 a.m. ET and will also participate in one-on-one meetings during the conference. A webcast of the company's presentation will be available on the Events page of the Investor Relations section of Mustang's website, www.mustangbio.com, for approximately 30 days after the meeting.

Mustang Bio to Present at the Raymond James Human Health Innovation Conference

CytRx

Fortress Biotech

MEI Pharma

Matinas BioPharma Hlds

Orphazyme A/S

Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts

Colony Capital Inc. - Ordinary Shares - Class A

iPower Inc

VistaGen Therapeutics

Waterdrop

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Buy-Rated Stocks Trading Below $10 With Outstanding Upside Potential

The stock price of Mustang Bio Inc (NASDAQ: MBIO) increased by over 7% pre-market. These are the details.

MBIO Stock Price: Over 7% Increase Explanation

Mustang Bio Inc (NASDAQ: MBIO) has updated interim data from the ongoing Phase 1/2 trial evaluating MB-106 for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL). The data were presented at the European Hematology Association 2021 Virtual Congress.

Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial

Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Aptose Biosciences

Regulus Therapeutics

These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Mustang Bio Stock (MBIO)